Verve Therapeutics (NASDAQ:VERV) just reported results for the second quarter of 2024.
- Verve Therapeutics reported earnings per share of -59 cents. This was above the analyst estimate for EPS of -68 cents.
- The company reported revenue of $6.69 million.
- This was 178.83% better than the analyst estimate for revenue of $2.40 million.